NCT01432886View on ClinicalTrials.gov

A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

December 31, 2013

Conditions
Breast Cancer
Interventions
DRUG

E7389

Eribulin mesylate (iv) will be administered on Day 1 and Day 8 of each cycle (3 weeks as 1 cycle). Trastuzumab (iv) will be administered as weekly use or tri-weekly use. Trastuzumab will be administered immediately after eribulin mesylate administration when used concomitantly.

Trial Locations (2)

Unknown

Kashiwa-shi

Hidaka-shi

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT01432886 - A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer | Biotech Hunter | Biotech Hunter